N-Dodecanoyl-NBD-ceramide trihexoside惠诚进口

H1631-001

N-Dodecanoyl-NBD-ceramide trihexoside

semisynthetic

C₅₄H₉₁N₅O₂₁

1145

1mg

solid

98+% TLC

N-C12:0-NBD-CTH; N-C12:0-NBD-Globotriaosylceramide

DMSO, hot methanol, chloroform/methanol, 2:1

-20°C

1. J. Kok et al. “Dihydroceramide Biology STRUCTURE-SPECIFIC metaBOLISM AND INTRACELLULAR LOCALIZATION” Journal of Biological Chemistry, Vol. 272 pp. 21128-21136, 1997
2. J. Hsu et al. “Enhanced endothelial delivery and biochemical effects of
-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease” Journal of Controlled Release, doi:10.1016/j.jconrel.2010.10.031, 2010
3. J. E. Groener, B. J. Poorthuis, S. Kuiper, M. T. Helmond, C. E. Hollak, J. M. Aerts. “HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma.” Clin Chem., Apr;53(4):742-7, 2007. Epub Mar 1 2007
4. K. Mills, A. Johnson, B. Winchester. “Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry.” FEBS Lett., Mar 27;515(1-3):171-6, 2002
5. C. Menge, I. Stamm, M. Wuhrer, R. Geyer, L. H. Wieler, G. Baljer. “Globotriaosylceramide (Gb(3)/CD77) is synthesized and surface expressed by bovine lymphocytes upon activation in vitro.” Vet Immunol Immunopathol., Nov;83(1-2):19-36, 2001